ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial

BACKGROUND: Cisplatin-radiotherapy is a preferred standard for locally advanced, head and neck squamous cell carcinoma (HNSCC). However, the cisplatin-attributable survival benefit is small and toxicity substantial. A biomarker of cisplatin resistance could guide treatment selection and spare morbid...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauman, J E, Austin, M C, Schmidt, R, Kurland, B F, Vaezi, A, Hayes, D N, Mendez, E, Parvathaneni, U, Chai, X, Sampath, S, Martins, R G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798971/
https://www.ncbi.nlm.nih.gov/pubmed/24064970
http://dx.doi.org/10.1038/bjc.2013.576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798971/
https://www.ncbi.nlm.nih.gov/pubmed/24064970
http://dx.doi.org/10.1038/bjc.2013.576

Ejemplares similares